• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A comment on the International Society of Geriatric Oncology guidelines: evidence-based advice for the clinical setting.国际老年肿瘤学会指南述评:临床实践的循证建议。
Oncologist. 2012;17 Suppl 1(Suppl 1):31-5. doi: 10.1634/theoncologist.2012-S1-31.
2
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.老年男性前列腺癌的管理:国际老年肿瘤学会工作组的建议。
BJU Int. 2010 Aug;106(4):462-9. doi: 10.1111/j.1464-410X.2010.09334.x. Epub 2010 Mar 25.
3
Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients.国际老年肿瘤学会关于老年前列腺癌患者管理的最新建议。
Eur J Cancer. 2019 Jul;116:116-136. doi: 10.1016/j.ejca.2019.04.031. Epub 2019 Jun 10.
4
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.为制定老年男性前列腺癌管理 SIOG 指南而提出的背景。
Crit Rev Oncol Hematol. 2010 Jan;73(1):68-91. doi: 10.1016/j.critrevonc.2009.09.005.
5
Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.老年前列腺癌患者的管理:国际老年肿瘤学会工作组的建议。
Eur Urol. 2017 Oct;72(4):521-531. doi: 10.1016/j.eururo.2016.12.025. Epub 2017 Jan 11.
6
Management of metastatic prostate cancer: the crucial role of geriatric assessment.转移性前列腺癌的管理:老年评估的关键作用。
BJU Int. 2008 Mar;101 Suppl 2:23-9. doi: 10.1111/j.1464-410X.2007.07486.x.
7
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology.老年前列腺癌患者的管理:国际老年肿瘤学会工作组的最新建议。
Lancet Oncol. 2014 Aug;15(9):e404-14. doi: 10.1016/S1470-2045(14)70018-X.
8
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.EAU-ESTRO-SIOG 前列腺癌诊治指南。第二部分:复发、转移和去势抵抗性前列腺癌的治疗。
Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.
9
Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?老年转移性去势抵抗性前列腺癌患者:我们应该用化疗治疗吗?
Cancer Treat Rev. 2017 Apr;55:173-180. doi: 10.1016/j.ctrv.2017.03.007. Epub 2017 Apr 3.
10
Geriatric assessment in daily oncology practice for nurses and allied health care professionals: Opinion paper of the Nursing and Allied Health Interest Group of the International Society of Geriatric Oncology (SIOG).老年肿瘤护理评估:国际老年肿瘤学会(SIOG)护理和联合健康护理兴趣小组的观点文件。
J Geriatr Oncol. 2016 Sep;7(5):315-24. doi: 10.1016/j.jgo.2016.02.006. Epub 2016 Mar 5.

引用本文的文献

1
Prostate Cancer in Male Seniors Part 2: Treatment.老年男性前列腺癌 第二部分:治疗
Fed Pract. 2015 Aug;32(Suppl 7):36S-40S.
2
Challenges of managing elderly men with prostate cancer.管理老年前列腺癌男性患者的挑战。
Nat Rev Clin Oncol. 2014 Jun;11(6):354-64. doi: 10.1038/nrclinonc.2014.71. Epub 2014 May 13.
3
Radical radiotherapy for high-risk prostate cancer in older men.根治性放疗治疗老年高危前列腺癌。
Oncologist. 2012;17 Suppl 1(Suppl 1):9-15. doi: 10.1634/theoncologist.2012-S1-09.

本文引用的文献

1
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.在后多西他赛治疗环境下转移性前列腺癌的新型治疗策略。
Oncologist. 2011;16(11):1487-97. doi: 10.1634/theoncologist.2010-0412. Epub 2011 Nov 2.
2
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
3
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中,泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
4
Trends in the treatment of localized prostate cancer using supplemented cancer registry data.利用补充癌症登记数据评估局限性前列腺癌的治疗趋势。
BJU Int. 2011 Feb;107(4):576-84. doi: 10.1111/j.1464-410X.2010.09514.x. Epub 2010 Aug 24.
5
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.老年男性前列腺癌的管理:国际老年肿瘤学会工作组的建议。
BJU Int. 2010 Aug;106(4):462-9. doi: 10.1111/j.1464-410X.2010.09334.x. Epub 2010 Mar 25.
6
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.为制定老年男性前列腺癌管理 SIOG 指南而提出的背景。
Crit Rev Oncol Hematol. 2010 Jan;73(1):68-91. doi: 10.1016/j.critrevonc.2009.09.005.
7
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.70岁以上男性在前列腺特异性抗原早期和晚期阶段患前列腺癌的风险更高,生存率更低。
J Urol. 2009 Nov;182(5):2242-8. doi: 10.1016/j.juro.2009.07.034. Epub 2009 Sep 16.
8
Future of cancer incidence in the United States: burdens upon an aging, changing nation.美国癌症发病率的未来:老龄化、不断变化的国家所面临的负担。
J Clin Oncol. 2009 Jun 10;27(17):2758-65. doi: 10.1200/JCO.2008.20.8983. Epub 2009 Apr 29.
9
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.多西他赛或米托蒽醌治疗激素难治性前列腺癌:TAX-327研究中前列腺特异性抗原、疼痛、生活质量反应与生存之间的关系
Clin Cancer Res. 2008 May 1;14(9):2763-7. doi: 10.1158/1078-0432.CCR-07-0944.
10
Management of metastatic prostate cancer: the crucial role of geriatric assessment.转移性前列腺癌的管理:老年评估的关键作用。
BJU Int. 2008 Mar;101 Suppl 2:23-9. doi: 10.1111/j.1464-410X.2007.07486.x.

国际老年肿瘤学会指南述评:临床实践的循证建议。

A comment on the International Society of Geriatric Oncology guidelines: evidence-based advice for the clinical setting.

机构信息

Department of Surgery, Mater Misericordiae Hospital and University College Dublin, Irish Cancer Society, 43/45 Northumberland Road, Dublin 4, Ireland.

出版信息

Oncologist. 2012;17 Suppl 1(Suppl 1):31-5. doi: 10.1634/theoncologist.2012-S1-31.

DOI:10.1634/theoncologist.2012-S1-31
PMID:23015683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3593782/
Abstract

Largely a disease of older men, prostate cancer is likely to become a growing burden in the developed world as the population ages and overall life expectancy increases. Furthermore, prostate cancer management in older men is not optimal, reflecting the lack of training dedicated to senior adults in fellowship programs and the lack of specific guidelines to manage senior adults. The International Society of Geriatric Oncology (SIOG) convened a multidisciplinary Prostate Cancer Working Group to review the evidence base and provide advice on the management of the disease in senior age groups. The Working Group reported that advancing age, by itself, is not a reliable guide to treatment decision making for men with either localized or advanced prostate cancer. Instead, the SIOG guidelines advise health care teams to assess the patient's underlying health status, which is largely dictated by associated comorbid conditions, but also by dependency in activities of daily living and nutritional status, and to use the findings to categorize the individual into one of four groups: healthy, vulnerable, frail, or terminally ill. The guidelines recommend that a patient categorized as healthy or vulnerable (i.e., with reversible problems following geriatric intervention) should receive the same approach to treatment as a younger patient. Frail patients should be managed using adapted treatment strategies, and the terminally ill should receive symptomatic/palliative care only. The guidelines may have ongoing relevance as the treatment options for prostate cancer expand.

摘要

前列腺癌主要发生于老年男性,随着人口老龄化和预期寿命的延长,前列腺癌在发达国家的发病率将不断增加,其负担也将不断加重。此外,由于老年男性相关培训项目缺乏对老年人的专门培训,以及缺乏专门针对老年人的管理指南,前列腺癌的治疗效果并不理想。国际老年肿瘤学会(SIOG)召集了一个多学科前列腺癌工作组,对现有证据进行了审查,并就老年患者前列腺癌的管理提供了建议。工作组报告称,对于局限性或晚期前列腺癌患者,年龄增长本身并不能作为治疗决策的可靠依据。相反,SIOG 指南建议医疗团队评估患者的基础健康状况,这主要取决于合并症情况,但也取决于日常生活活动的依赖性和营养状况,并根据这些评估结果将患者分为以下 4 个组别之一:健康、脆弱、虚弱或终末期。指南建议,将被归类为健康或脆弱(即经过老年干预后可逆转的问题)的患者应接受与年轻患者相同的治疗方法。虚弱的患者应采用适应性治疗策略进行治疗,而终末期患者则仅接受对症/姑息治疗。随着前列腺癌治疗方法的不断扩展,这些指南可能会持续具有重要意义。